Lamark Biotech
Hyderabad, India· Est.
Thermostable biologics platform that makes insulin, AMD and cancer therapies affordable without refrigeration.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Thermostable biologics platform that makes insulin, AMD and cancer therapies affordable without refrigeration.
DiabetesOphthalmologyOncology
Technology Platform
Proteostrong™ proprietary formulation technology that stabilizes therapeutic proteins for thermostability, eliminating the need for cold‑chain storage.
Opportunities
Large unmet need for affordable, refrigeration‑independent biologics in emerging markets; potential to license reformulated versions of high‑value proteins to global pharma partners.
Risk Factors
Technical risk of maintaining efficacy after thermal stress; regulatory acceptance of reformulated biologics; competition from other thermostable protein platforms.
Competitive Landscape
Competes with firms developing thermostable vaccines and proteins (e.g., GSK, Amgen), but differentiates through its proprietary Proteostrong™ chemistry and focus on existing high‑value biologics.